India has approved Eli Lilly Mounjaro KwikPen in six doses, days after Novo Nordisk Wegovy pen launch. Both GLP-1 drugs target obesity and diabetes. As demand surges, Indian pharma giants like Sun, Cipla, and Zydus race to develop cheaper versions, with semaglutide patent set to expire next year in India.